Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRKAB1, TMEM233 and CCDC60 antisense RNA 1 (PRKAB1-AS1)
- Target
- PRKAB1-AS1
- Molecular classification
- Antisense RNA, Long non-coding RNA (lncRNA)
01
Overview
PRKAB1-AS1 is a long non-coding antisense RNA gene transcribed from the opposite strand of the genomic locations encoding PRKAB1, TMEM233, and CCDC60. It belongs to the lncRNA class and is presumed to regulate the expression of these genes by base pairing to their RNA transcripts, influencing transcription, translation, and epigenetic states. While antisense RNAs play important regulatory roles and are being explored for therapeutic applications, PRKAB1-AS1 itself is not recognized as a conventional therapeutic target in current databases and literature. No interacting drugs, direct mechanisms of action, or biomarker/safety data specific to PRKAB1-AS1 have been established.
- Other names
- PRKAB1-AS1PRKAB1, TMEM233 and CCDC60 antisense RNA 1lncRNA PRKAB1-AS1 (informal)HGNC: 58183NCBI Gene: 105370027Ensembl: ENSG00000248636
02
Mechanism of action
Not applicable for drugs; for antisense RNAs generally, gene expression silencing via base pairing and degradation, modulation of chromatin accessibility, and interference in transcriptional regulation
03
Biological functions
Gene expression regulationEpigenetic regulationTranscriptional interference or activation (by base pairing with sense transcripts)Possible involvement in alternative splicing, RNA stability, chromatin modification (general lncRNA roles)
04
Disease associations
Likely Cancer (via dysregulation of antisense RNA in various cancers; general lncRNAs and antisense RNAs are implicated, but specific disease association for PRKAB1-AS1 is not confirmed in the literature)Other (possible involvement in cardiovascular and viral diseases for other antisense RNAs, but not established for PRKAB1-AS1 itself)Direct mechanistic/disease roles for PRKAB1-AS1 have not been reported in the top databases
05
Safety considerations
None specific to PRKAB1-AS1; in general, therapeutic manipulation of antisense RNAs (via antisense oligonucleotides) can have off-target and immunogenicity risks
06
Interacting drugs
None (no approved or experimental drugs listed as directly interacting with PRKAB1-AS1; antisense oligonucleotides target other RNAs, but not this one)
07
Biomarkers
None specific to PRKAB1-AS1; lncRNAs and antisense RNAs in general are studied as putative biomarkers
Beyond the preview
Go deeper on PRKAB1, TMEM233 and CCDC60 antisense RNA 1 (PRKAB1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRKAB1, TMEM233 and CCDC60 antisense RNA 1 (PRKAB1-AS1).